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Abstract
The most recently characterized H4 histamine receptor (H4R) is expressed preferentially in the bone marrow, raising the
question of its role during hematopoiesis. Here we show that both murine and human progenitor cell populations express
this receptor subtype on transcriptional and protein levels and respond to its agonists by reduced growth factor-induced
cell cycle progression that leads to decreased myeloid, erythroid and lymphoid colony formation. H4R activation prevents
the induction of cell cycle genes through a cAMP/PKA-dependent pathway that is not associated with apoptosis. It is
mediated specifically through H4R signaling since gene silencing or treatment with selective antagonists restores normal
cell cycle progression. The arrest of growth factor-induced G1/S transition protects murine and human progenitor cells from
the toxicity of the cell cycle-dependent anticancer drug Ara-C in vitro and reduces aplasia in a murine model of
chemotherapy. This first evidence for functional H4R expression in hematopoietic progenitors opens new therapeutic
perspectives for alleviating hematotoxic side effects of antineoplastic drugs.
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Introduction
Histamine is one of the most versatile biogenic amines with
pleiotropic activities, including regulatory functions during the
immune response and hematopoiesis [1–3]. This functional
diversity results from the variety of its modes of intervention
through extra- and intracellular binding sites and specific
receptors, triggering different signal transduction pathways [4–
6]. The final outcome of these interactions is quite complex, as it
depends on how receptors are distributed on target cells, according
to their microenvironment and stage of development [7,8].
Even though the most recently discovered H4R is mainly
expressed in the bone marrow (BM) [9], its potential role during
hematopoiesis has not been addressed. To date, its most clearly
established functions consist in recruitment and activation of
hematopoietic cells involved in inflammatory responses, such as
eosinophils, mast cells, neutrophils and dendritic cells [10–14].
Because of these activities, together with H4R-induced IL-16
production by CD8 cells [15] and alleviation of experimental allergic
asthma in H4R-deficient mice [16], this receptor is considered a
potential pharmacological target for anti-inflammatory therapy [17].
Histamine has been implicated in the regulation of hematopoi-
etic progenitor cells by several studies, including those of J. W.
Byron and our own [18,19]. These activities have been ascribed to
H1 and H2 histamine receptors, the only subtypes known at the
time. The discovery of an additional H4R, together with its
predominant expression in the bone marrow, prompted us to
reassess this issue. Here we report that the H4R is preferentially
expressed and functional in progenitor-enriched murine and
human hematopoietic cells, as it mediates a reversible cAMP/
PKA-dependent cell cycle arrest that causes reduced proliferation
and colony formation in methylcellulose. Based on the notion that
quiescence protects clonogenic cells from growth-dependent
cytotoxicity, we investigated whether H4R activation could
become instrumental in a clinical setting to prevent myeloablation
in a murine model of chemotherapy.
Results
Functional H4R expression in murine hematopoietic
progenitor cells
We assessed the expression of the H4R in total and progenitor-
enriched bone marrow (BM) populations by staining with specific
antibodies. As shown in Fig. 1A, the proportion of positive cells




+ cells, which proved that the receptor is
mainly expressed in the immature compartment. Murine bone
marrow-derived mast cells are shown as a positive control.




with anti-H4R antibody compared with irrelevant isotype control and anti-H4R antibody saturated with blocking peptide. BM-derived murine mast
cells served as a positive control. (B) Cell cycle arrest in sorted progenitor-enriched c-kit
+ BM cells after a 2-h incubation in StemSpan medium
supplemented with growth factor cocktail (GF), with or without histamine or CB at a concentration of 10
25 M. The cell cycle status was analyzed after
staining with Vybrant DyeCycle Violet (VDV) as compared with freshly isolated cells. (C) Reversal of H4R-induced cell cycle arrest. Sorted c-kit
+ cells
were incubated for 3 days with or without CB in StemSpan medium supplemented with growth factor cocktail. The cell cycle status was then
assessed before and after further incubation of extensively washed cells with growth factors for 24 h. Data are means6SD from 2 experiments.
Unstained apoptotic cells were not detected. (D) Recovery of normal cell cycling in the presence of a selective H4R antagonist. Sorted c-kit
+ BMC were
incubated for 3 days with growth factors (GF) alone or together with histamine (HA) or CB at a concentration of 10
25 M, with or without prior
exposure to JNJ 7777120 (10
25 M). Means6SEM from 3 experiments. (E) H4R silencing in c-kit
+ BM cells. H4R expression was evaluated 24 h after
transfection (.90% efficiency). The effect of gene silencing on CB-induced cell cycle arrest was assessed following overnight incubation. Means6SEM
from 3 experiments.
doi:10.1371/journal.pone.0006504.g001
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PLoS ONE | www.plosone.org 2 August 2009 | Volume 4 | Issue 8 | e6504We evaluated the function of the H4R, by examining the effect
of histamine, its natural ligand, and clobenpropit (CB), one of its
most potent agonists, on the cell cycle status of sorted c-kit
+ BM
cells, which comprise a heterogenous population of progenitors at
various differentiation stages. As shown in Fig. 1B, these cells are
mostly quiescent at t0, but enter the cell cycle in response to a
growth factor cocktail composed of IL-3, IL-6 and SCF. Both
histamine and CB inhibited growth factor-induced cell cycle
progression at an optimal dose of 10
25 M (dose-response curve in
Figure S1), as illustrated by the accumulation of cells in stage G0/
G1 and decrease in G2/S. The cell cycle arrest persisted after 3
days in the presence of CB, but could by reversed upon its removal
by a 24-h exposure to growth factor cocktail (Fig. 1C). Apoptosis
was not induced in these conditions, as assessed by Annexin-V/PI
staining illustrated by the dot plots of a typical experiment in
Figure S2.
Though initially developed as an H3R antagonist, CB is H4R-
specific in BM cells, which do not express the H3R [5].
Pretreatment with the selective H4R antagonist JNJ7777120
[20] before exposure to histamine or CB (Fig. 1D) prevented the
cell cycle arrest, providing an additional argument in favor of H4R
specificity. This was confirmed by a similar effect of the antagonist
JNJ10191585 and the reverse agonist thioperamide (Figure S3).
Finally, growth factor-induced cell cycle progression was restored
in progenitor-enriched ckit
+ BM cells transfected with siRNA to
knock down H4R expression before exposure to CB (Fig. 1E).
This treatment did effectively diminish H4R expression on protein
levels, proving the specificity of the effect.
H4R-mediated inhibition of cell proliferation and/or
differentiation of clonogenic progenitors
The inhibition of growth factor-induced G1/S transition in the
presence of CB led to reduced proliferation and/or differentiation,
as revealed 1) by the maintenance of c-kit expression among
progenitor-enriched cells depleted for mature BM components
(Lin
-) after a 3-day culture in the presence of CB (Fig. 2A) and 2)
by a reduced number of cell divisions measured by CFSE tracking
(Fig. 2B), relative to growth factor-stimulated controls. H4R
activation inhibited likewise the proliferation of more primitive
sorted c-kit
+Sca1
+ cells (7865% inhibition in response to CB after
3 days of culture with growth factor cocktail; mean6SEM; n=3),
in agreement with their H4R expression (Fig. 1A). As shown in
Fig. 2C, it caused a marked decrease in both myeloid (CFU-GM)
and lymphoid (CLP) colony formation in methylcellulose. A
comparable inhibition occurred in the HALO-Hemogenix
luminescence assay, set up with different growth factor cocktails
to reveal proliferation of progenitors with distinct differentiation
potentials (CFU-C, CFU-C+BFU-E and CFU-C+BFU-E+CFU-
GEMM) (Fig. 2C). Once again, the H4R antagonist JNJ7777120
reversed the inhibition of CB on IL-3-induced colony formation
(10.565.1% in the presence of JNJ versus 55.1610.3% in
response to CB alone; n=3).
Impaired expression of cell cycle proteins through cAMP/
PKA-dependent signaling triggered by H4R engagement
We examined the impact of H4R activation on the expression of
genes encoding cell cycle proteins. As shown in Fig. 3A, the
overall transcription of growth factor-induced cell cycle genes
(oligo GEArrayH 0MM-020) decreased strikingly upon exposure to
CB, almost to the level of freshly isolated cells. Further analysis of
cyclins expressed typically during G1/S transition [21] established
that both cyclin D3 and E were markedly decreased in response to
CB, as demonstrated by FACS and Western blot analysis (Fig. 3B
and C, respectively). In addition, the H4R agonist prevented





CB did no longer inhibit cell cycling in progenitor-enriched BM
cells treated with Bordetella pertussis toxin (PTX), which confirmed
the involvement of Gi/o protein coupling in the initiation of the
signal transduction pathway (Fig. 4A). The decrease of intracel-
lular cAMP levels is critical for cell cycle arrest that is counteracted
by adding exogenous dbcAMP, a cell-permeable analogue of this
signal carrier (Fig. 4B). In further support of this mechanism of
action, CB inhibited cell cycle progression induced by forskolin,
commonly used to raise intracellular cAMP levels. As shown in
Fig. 4C, it did not affect the expression of Erk, conversely to other
models in which a crosstalk between cAMP and the ERK/MAPK
pathway has been described [22]. The PKA/CREB pathway is
the most likely candidate for downstream signaling [23], given that
the PKA inhibitor Rp-8-Br-cAMPS mimicked the effect of CB
(Fig. 4D).
H4R-mediated in vitro and in vivo protection of murine
hematopoietic progenitor cells against the toxicity of
anti-cancer drugs
We argued that H4R-induced cell cycle arrest, which is
reversible and not associated with apoptosis, might provide a
strategy for myeloprotection. To test this assumption in vitro,w e
pretreated murine BM cells with or without CB, before stimulating
their entry into cell cycle in response to growth factors, followed by
exposure to the cell cycle-dependent anti-cancer drugs AraC or
hydroxy-urea (HU). We then assessed their clonogenic potential in
the methylcellulose colony-forming assay, as shown in Fig. 5A.
We found that this treatment protected a substantial proportion of
clonogenic progenitors, which opened the way for in vivo
experiments, to verify whether cell cycle arrest occurred in mice
having received repeat injections of CB. As shown in Fig. 5B, this
turned out to be the case since the proportion of progenitor-
enriched c-kit
+ BM cells in phase G0/G1 of the cell cycle was
significantly higher among cells recovered from mice having
received CB before stimulation with growth factor cocktail than
among their saline-injected counterpart.
We assessed myeloprotection through H4R activation in a
model of cell cycle-dependent chemotherapy, following the
schedule represented in Fig. 5C. At day 2 post AraC CB
maintained significantly higher BM and white blood cell counts
relative to AraC alone (Fig. 5D and E). This was likewise true for
clonogenic cells evaluated in the methylcellulose assay (Fig. 5F).
Treatment with CB alone had no significant effect on either of
these parameters (Fig. 5D-F) and had no other adverse
consequences. Following the same injection schedule, CB provided
also a partial protection of medullary colony-forming cells 2 days
post treatment of mice with the antineoplastic drug cyclophos-
phamide (300 mg/kg), a mobilizing agent that is only partially cell
cycle-dependent (Fig. 5E).
H4R-induced cell cycle arrest in human hematopoietic
progenitor cells
We addressed the question whether the H4R was also expressed
and functional in human hematopoietic progenitor cells. As shown
in Fig. 6A, the most immature CD34
high cells isolated from cord
blood and expanded for 3 days in growth factor cocktail were
largely H4R-positive. Furthermore, their proliferation in response
to the growth factor cocktail was clearly inhibited upon exposure
to the agonist CB (3.861.4610
6 cells in response to growth factor
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PLoS ONE | www.plosone.org 3 August 2009 | Volume 4 | Issue 8 | e6504Figure 2. H4R-mediated inhibition of clonogenic cell proliferation and/or differentiation. (A) Maintenance of c-kit expression by Lin
- BMC
incubated for 3 days in growth factor cocktail (GF) together with CB (10
25 M), as compared with c-kit
+ cells freshly sorted or cultured in GF alone. (B)
Decreased number of cell divisions upon H4R stimulation. After staining with CFSE, Lin
2 BM cells were incubated for 3 days in growth factor cocktail
with or without CB. CFSE fluorescence intensity was analyzed among gated c-kit
+ cells. (Means6SEM from 6 experiments. *P=0.013 **P=0.0022). A
typical FACS profile is shown. (C) Inhibition of colony formation from total BM cells in the presence of CB. Cells were seeded into MethoCult
supplemented with 1 ng/ml of mrIL-3 to generate granulocyte/macrophage colonies or with SCF (100 ng/ml)+IL-7 (10 ng/ml+Flt-3-L (20 ng/ml) to
reveal common lymphoid progenitors (CLP). CB was added at a concentration of 10
25 M and colonies were scored after 7 days of culture.
Means6SEM. from 3 experiments. The right panel depicts the results obtained with the HALO
TM-Hemogenix assay based on luminescence output in
response to growth factor cocktails revealing CFU-GM, CFU-GM+BFU-E and CFU-GM+BFU-E+CFU-GEMM. Means6SEM from quadruplicate
determinations.
doi:10.1371/journal.pone.0006504.g002
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PLoS ONE | www.plosone.org 4 August 2009 | Volume 4 | Issue 8 | e6504Figure 3. H4R activation impairs the expression of cell cycle proteins. (A) The effect of 10
25 M CB on the expression of cell cycle genes was
assessed in freshly isolated c-kit
+ BM cells and after a 3-h exposure to growth factor cocktail (GF) with or without CB, using a cell cycle Oligo GEArray.
Fold decrease upon exposure to CB: 35 for cyclin D3: and: 54 for cyclin E. (B) Decreased intracellular staining with FITC-conjugated anti-cyclin D3
antibody after an overnight incubation of sorted c-kit
+ cells in the presence of CB, as compared with growth factors alone. Data represent a typical
dot plot and means6SEM from 3 experiments. (C) Western blot analysis in whole-cell extracts before and after a 5-h incubation of sorted c-kit
+ cells
with growth factors alone or together with CB.
doi:10.1371/journal.pone.0006504.g003
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6 in the presence of CB after 3
days of culture starting from 10
6 cells; means6SEM; n=5), in
accordance with an induction of the cell cycle arrest. Indeed, H4R
activation decreased the number of cell divisions, evaluated by
CFSE staining (Fig. 6B) and slowed down cell cycle progression
by increasing the percentage of cells in G0/G1 (Fig. 6C). Cell
Figure 4. CB-induced cell cycle arrest is mediated through Gi/o proteins and cAMP/PKA-dependent signaling. (A) Sorted c-kit
+ BM cells
were exposed for 2 h to growth factor cocktail with or without CB and/or PTX (100 ng/ml). The cell cycle status was analyzed after staining with
Vybrant DyeCycle Violet (VDV), in comparison with freshly isolated cells. Means6SEM from 3 experiments. (B) Critical role of cAMP in CB-induced cell
cycle arrest. Sorted c-kit
+ BM cells were incubated for 2 h in StemSpan medium with growth factor cocktail or forskolin (FK; 10
25 M) with or without
CB, dbcAMP alone or together with growth factors and CB. The cell cycle status was assessed by Vybrant DyeCycle Violet (VDV) staining. Data
represent typical cell cycle profiles and means6SEM from 3 experiments. (C) Western blot analysis of Erk expression in freshly isolated c-kit
+ cells and
after 5 h of incubation with growth factor cocktail (GF) with or without CB. (D) The PKA inhibitor Rp-8-Br-cAMPS mimics the cell cycle arrest induced
by CB in sorted c-kit
+ BM cells stimulated with growth factor cocktail. The cell cycle status was evaluated by VDV staining after a 2-h incubation.
doi:10.1371/journal.pone.0006504.g004
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PLoS ONE | www.plosone.org 6 August 2009 | Volume 4 | Issue 8 | e6504Figure 5. H4R-induced cell cycle arrest in murine hematopoietic progenitors in vivo and protection against the cytotoxicity of cell
cycle-dependent chemotherapeutic compounds. (A) BM cells were pretreated for 24 h with CB, before exposure to AraC (10 mg/ml), or
hydroxy-urea (HU; 10
23 M). After a 1-h incubation, cells were extensively washed and plated in methylcellulose in the presence of IL-3 (1 ng/ml). 7
days later colonies were scored and survival with or without CB was evaluated relative to saline controls. (B) BM cells were recovered 4 h after the last
of three injections of CB or saline (30 mg/kg each). The cell cycle status of gated Lin
2 cells was evaluated in vitro after exposure to growth factors
overnight (means6SEM; n=3). (C) Injection schedule of CB in AraC- or cyclophosphamide-treated mice. (D-G) Total WB and BM cells were counted 2
days after injection of AraC in mice having received 3 i.p. injections of CB (20 mg/kg each) or saline, as compared with CB alone, Means6SEM from 8
individual mice. CFU-GM were evaluated in the BM of mice having received AraC or cyclophosphamide 2 days before sacrifice. Data are means6SEM.
n=8 and n=2 in the AraC and cyclophosphamide series.
doi:10.1371/journal.pone.0006504.g005
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PLoS ONE | www.plosone.org 7 August 2009 | Volume 4 | Issue 8 | e6504Figure 6. H4R activation induces inhibition of cell cycle progression in human progenitor cells. (A) H4R expression in gated CD34
+ cells
sorted from cord blood after a 3-day expansion in StemSpan medium with growth factor cocktail. (B) Tracking of cell divisions by CFSE staining. After
expansion for 3 days, CD34
+ were stained with CFSE and incubated for further 3 days in StemSpan medium supplemented with growth factor cocktail
with or without CB. They were then labeled with PE-conjugated CD34 mAb and CFSE fluorescence intensity was measured in gated CD34
+ cells. Data
represent a typical experiment out of 2. (C) Cell cycle analysis. Cells were prepared as above, followed by staining with FITC-conjugated anti-CD34
mAb and PI. (Means6SEM; n=3. (D) H4R silencing in CD34
+ cells. H4R expression was evaluated 24 h after transfection (.90% efficiency) with
silencing and scrambled RNA. The effect of gene silencing on CB-induced inhibition of proliferation was assessed after a further 3-day incubation
when cells were counted and viability was assessed by trypan blue exclusion. Data represent means6SD from 2 experiments. (E) Protection of human
clonogenic cells against the toxicity of AraC. CD34
+ cells were pretreated for 24 h with CB, before exposure to AraC (10 mg/ml). After a 1-h incubation,
cells were extensively washed and plated in methylcellulose supplemented with growth factor cocktail. 14 days later colonies were scored and
survival with or without CB was evaluated relative to saline controls. (Means6SEM; n=3).
doi:10.1371/journal.pone.0006504.g006
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was not impaired in these conditions. As in the murine model,
H4R specificity was established by gene silencing that abolished
most of the anti-proliferative effect of CB on CD34
+ cells
stimulated with growth factor cocktail (Fig. 6D). A similar
restoration of cell growth occurred after receptor blockade by
JNJ7777120 (data not shown). Finally, a 24-h pretreatment with
CB before exposure to AraC was clearly protective, supporting
potential applications in a clinical setting (Fig. 6E).
H4R expression and function in cancer cell lines
It is generally acknowledged the H4R expression occurs mainly
in cells of hematopoietic origin. Nevertheless, the receptor has
been reported in two well-known human colon cancer cell lines,
HT29 and HCT116, and the mammary carcinoma MDA-MB-
231 [24,25], prompting us to verify whether the H4R agonist CB
inhibited their proliferation, which was not the case since at
optimal concentrations (10
25 M) neither the growth of these cells
(Fig. 7A) nor their sensitivity to the anti-neoplastic drug 5-FU
were affected, as illustrated for the HCT 116 cell line in Fig. 7B.
However, this result is not conclusive, inasmuch as we were unable
to confirm the H4R expression on transcriptional and protein
levels reported before (data not shown), which shows that it is
indeed essential to assess whether H4R is operational in the cancer
cells each time before considering a clinical application.
Discussion
In this study we provide the first demonstration that the H4R is
expressed in murine and human hematopoietic progenitor cells
and that its activation results in the inhibition of growth factor-
induced cell cycling. In our experimental setup histamine and CB,
which is also a H3R antagonist, target the H4R specifically, since
1) bone marrow cells do not express the H3R [5], 2) cell cycle
progression was restored when the H4R was blocked by selective
H4R antagonists before exposure to CB or histamine and 3) the
effect of CB was clearly reduced after H4R silencing. The H4R is
functional in hematopoietic progenitor cells since its stimulation
inhibited both myeloid and lymphoid colony formation, suggesting
a relatively broad distribution among different progenitor subsets
identified by their distinct clonogenic potential.
The signal transduction pathway leading from H4R engage-
ment to cell cycle arrest is initiated by Gi/o protein coupling
followed by a decrease of cAMP levels. Further downstream, it
entails downregulation of PKA activity since a specific inhibitor of
this enzyme mimicked the effect of CB. Notwithstanding the
increased evidence for a crosstalk between cAMP and the ERK/
MAPK pathway [22], Erk expression was not modified by
exposure to CB. It is therefore most likely that decreased cell
cycling is promoted through PKA/CREB signaling, as proposed
by others [23].
H4R stimulation resulted in a striking downregulation of cyclin
D3, whose expression is typically induced by mitogens [21]. Cyclin
E levels were likewise decreased, while CB prevented the growth
factor-induced decrease of the cyclin-dependent kinase inhibitor
p21
Cip1/Waf1, a cell cycle regulator with important functions in self-
renewal, differentiation and apoptosis of progenitor cells [26]. By
contrast, p27
Kip1 expression that has been associated with the
regulation of growth and/or differentiation of more lineage-
restricted progenitor cells [27] was decreased in the same
conditions. It is currently acknowledged that the suppression of
p27
Kip1 alone is not sufficient to induce hematopoietic progenitor
cell cycling [28], as p21
Cip1/Waf1 presumably compensates for its
loss to maintain quiescence [26].
The growth arrest in response to H4R stimulation occurred
both in vitro and in vivo. Indeed, murine progenitor-enriched bone
marrow cells recovered after injection of CB were less prompt to
enter the cell cycle in response to growth factor cocktail than
saline-injected controls. This cell cycle arrest was revealed only
when progenitors were induced to proliferate in response to
growth factors. Without stimulation, they were mostly quiescent,
and thus not affected by H4R activation. The reversibility of the
cell cycle arrest, the lack of apoptosis and in vivo toxicity qualified
H4R agonists as potential pharmacological tools to protect
clonogenic cells from the hematotoxicity of anti-cancer drugs,
which remains a major drawback of chemotherapy. This toxicity
can affect either all hematopoietic lineages or particular subsets,
depending on the anti-cancer drug used and the doses adminis-
tered [29]. Several approaches have been proposed to limit these
complications, such as autologous bone marrow transplantation at
high-dose chemotherapy [30] or treatment with growth factors like
Figure 7. Malignant cell proliferation and sensitivity to 5-FU
are not affected by C. (A) Proliferation of colon and mammary gland
carcinoma cells was assessed after 3 days of culture starting from 2610
5
cells in 1 ml. Cells were detached by trypsin digestion and counted after
staining with trypan blue. Data are means6SEM from three distinct
experiments. (B) HCT116 carcinoma cells set up at a concentration of
10
5/ml were pretreated 24 h with CB (10
25 M) before adding 5-FU
(Sigma) at a concentration of 10 mg/ml for 48 h. 2 typical experiments
are shown.
doi:10.1371/journal.pone.0006504.g007
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respectively [31,32]. Yet, despite their relative effectiveness in
accelerating hematopoietic recovery or allowing a more intensive
drug regimen, these treatments are expensive, difficult to handle
and not devoid of side effects. There is also some evidence that
repeated treatment with growth factors during multiple courses of
chemotherapy may deplete the stem cell compartment and give
rise to genomic alterations, even though these issues remain
controversial [33,34].
The use of negative regulators of hematopoietic progenitor
proliferation as a strategy to reduce the hematotoxicity of anti-
neoplastic drugs, while improving the anti-tumor activity by dose
intensification, has been proposed in previous studies [35]. Some
of these compounds have proved quite effective in vitro or in
murine in vivo models [36–37], but turned out to be less beneficial
in preclinical trials because of a number of side effects [38]. It has
also been reported that chemokines act in synergy to decrease the
percentage of progenitors in S phase, thus providing myeloprotec-
tion against cell cycle-dependent drugs in vitro and in vivo and
accelerating hematopoietic recovery [39]. It has not yet been
established whether this effect is direct or indirect and how
chemokine receptors are distributed on different hematopoietic
progenitor subsets.
Among the multiple biological activities ascribed to histamine,
its contribution to the regulation of cell proliferation is supported
by a number of reports in normal and tumor cells [40]. These
studies have produced numerous and often conflicting results,
probably because histamine exerts different effects depending on
its binding sites and their distribution on target cells. Although it is
generally acknowledged that H4Rs are mainly expressed in
hematopoietic cells, some H4R
+ tumor cell lines and colorectal
cancer biopsies have also been reported [24,25,41,42]. We failed
to confirm this result in the colon carcinomas, HT29 and
HCT116, and the mammary carcinoma MDA-MB-231. In
accordance with the lack of expression, we found that the H4R
agonist CB affected neither the proliferation of these malignant
cells nor did it decrease their sensitivity to in vitro treatment with
the antineoplastic drug 5-FU, which raises the question of the
reliability of results obtained with long-established cell lines.
It is obvious that in a clinical setting H4R expression in cancer
cells should be assessed in each patient before treatment and
avoided when positive. Note that the studies investigating the effect
of H4R activation on cancer cell cycle progression have given rise
to conflicting results so far. For example, in MDA-MB-231 cells
H4R activation has been shown to result in G0/G1 cell cycle
arrest followed by apoptosis [25], while in another report
histamine receptor-mediated cell cycle arrest occurred in G2/M,
once again followed by apoptosis and enhanced radio-sensitivity,
which would increase the therapeutic efficiency rather than protect
malignant cells [41]. It has also been proposed that H4R
expression is downregulated in colorectal tumour cells [42], as
compared with healthy tissue, which underscores once again the
requirement of individual tests.
In conclusion, our data provide evidence for a new site of
intervention of histamine, through which it can specifically slow
down cell cycle progression in hematopoietic progenitors. At this
point, we can only speculate on the physiological relevance of this
interaction in patho-physiological situations generating increased
histamine levels in hematopoietic organs. Nonetheless, this new
function of the H4R provides an original therapeutic strategy to
alleviate the side effects of chemotherapy by preventing clonogenic
progenitors from entering the cell cycle, rendering them less
susceptible to the toxicity of anti-cancer drugs. We have not
established so far whether the H4R is functional in hematopoietic
stem cells with long-term repopulation activity, which in any case
would be irrelevant in this particular context, because this
quiescent population is not affected by cell cycle-dependent drugs
[43]. The purpose of our approach is to limit the period of aplasia
by accelerating short-term reconstitution from more lineage-
restricted clonogenic progenitors without impairing the sensitivity
of cancer cells to the treatment. These clinical perspectives, which
might eventually facilitate chemotherapy dose and schedule




Animal experiments were performed according to the French
Institutional Committee.
CD34
+ cells were purified from cord blood recovered with the
parents’ written consent, in accordance with the recommendations
and approval of the Belgian Ethical Committee (Comite ´e ´thique
hospitalo-facultaire universitaire Lie `ge 707). The experiments
were with frozen purified CD34
+ cells in the research unit CNRS
UMR8147 were performed with the approval of the local Ethics
Committee (Comite ´ d’e ´thique de l’Ho ˆpital Necker).
Mice
6- to 8-week-old, specific pathogen-free, male or female
C57BL/6J mice were purchased from CERJ (Les Genest St. Isle,
France) and maintained in our animal facility. All mice were kept
in well-controlled animal housing facilities and had free access to
tap water and pellet food. Animal experiments were performed
according to the French Institutional Committee.
Cytokines, histamine receptor ligands, antibodies and
other compounds
Murine and human recombinant IL-3, IL-6, Flt3-L, GM-CSF
and SCF were purchased from R&D Systems (Abingdon, UK).
Thioperamide, histamine dihydrochloride, forskolin, dibutyryl
(db)cAMP and the PKA inhibitor Rp-8-Br-cAMPS were pur-
chased from Sigma-Aldrich (St.-Quentin Fallavier, France). The
H4R agonist clobenpropit dihydrobromide was from Tocris
(Ellisville, MO), as was the H4R antagonist JNJ10191585.
JNJ7777120 was provided by UCB-Pharma. TrueLabeling-
AMP
TM Linear RNA Amplification Kit and Oligo GEArrayH
Mouse cell cycle Microarray (OMM-020) were purchased from
SABiosciences (tebu-bio, France) The following appropriately
labeled antibodies were used: anti-mouse CD117 (c-kit) (2B8),
TCRb (H57-597), Ly-6G(Gr-1) (RB6-8C5), CD11b (M1/70),
CD45R(B220) (RA3-6B2), CD4 (H129.19), CD8 (53–6.7), CD19
(1D3), TER-119, Ly-6A/E (Sca-1) (D7) and anti-human CD34
(581) (all from Pharmingen, San Diego, CA). Polyclonal goat anti-
human and anti-mouse H4R Abs, donkey anti-goat-FITC,
corresponding blocking peptides and irrelevant control goat Abs
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
FITC-conjugated anti-cyclin D3 and isotype controls were likewise
from Santa Cruz. Bordetella pertussis toxin was from Calbiochem (La
Jolla, CA).
Cell preparations, FACS analysis and sorting
Bone marrow and spleen cells were recovered and suspended in
culture medium, as previously described [5]. Peripheral blood was
collected from the retro-orbital sinus and nucleated cells were
counted on a MS9-5 Hematology Counter (Melet Schloesing
Laboratories, Osny, France). CD34
+ cells were purified from cord
blood recovered with the parents’ consent, in accordance with the
H4R-Induced Cell Cycle Arrest
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sorted magnetically using the positive selection kit purchased from
Miltenyi (Bergisch-Gladbach, FRG).
Cell suspensions were incubated on ice in the presence of rat
anti-mouse CD16/CD32 mAb (1 mg/10
6 cells, Pharmingen) to
block Fc receptor functions prior to specific staining with
appropriately labeled antibodies. For intracellular labeling with
anti-H4R and anti-cyclin D3 antibodies cells were treated with
FACS permeabilizing solution from BD before staining Cells were
analyzed in a FACSCanto II cytofluorometer (Becton Dickinson,
Mountain View, CA), using FlowJo software. Erythrocytes and
debris were excluded on the basis of forward and side scatter
parameters. At least 10,000 cells were acquired within the live
gate.
Lin
2 cells designate a progenitor-enriched population express-
ing neither myeloid nor lymphoid lineage markers (negative for
CD11b, Gr-1, CD19, TCRb). Lin
2 and c-kit
+ cells (.95% purity)
were isolated using the SpinSep depletion kit and the positive
selection kit with the RoboSep automaton from StemCell
Technologies, respectively. After staining, c-kit
+Sca1
+ cells were
further sorted electronically using a FACSVantage
TM cell sorter
(Becton Dickinson). The effect of CB on apoptosis of progenitor-
enriched BMC was evaluated using an Annexin-V staining kit






+ cells were suspended
at a final concentration of 10
5 cells per ml in serum-free StemSpan
medium (StemCell Technologies) and cultured up to 3 days in the
presence of 10 ng of IL-3, 10 ng of IL-6 and 50 ng of SCF per ml,
with or without CB (10
25 M). They were examined at different
time points for cell cycle progression as well as phenotypic and
morphologic characteristics, using cytometry and light microscopy
analysis of MGG-stained cytospin preparations.
Murine CFU-GM and human CFU-C were quantified in
MethoCult M3230 (StemCell Technologies) supplemented with
IL-3 alone (1 ng/ml) and in MethoCult GF H4434 (complete with
growth factors), respectively. They were plated in a final volume of
1 ml at a concentration of 5610
4 total BM cells/culture dish
(Falcon 1008) for murine and 5000 CD34
+ cells/ml for human
progenitors. Colonies were scored on day 7 and day 14,
respectively. In vitro protection against myelotoxic AraC (Cytara-
bine, Pfizer) and hydroxy-urea (Sigma) was evaluated after a 24-h
pretreatment of total BMC or CD34
+ cells with CB (10
25 M),
followed by exposure to 10 mg/ml of AraC or 10
23 M hydroxy-
urea (murine) for 1 h, extensive washing and colony-forming
assay.
In some experiments clonogenic progenitors were evaluated in
the HALO
TM-Hemogenix assay (Hemogenix Inc., Colorado
Springs, CA) based on luminescence output using adequate
growth factor cocktails for CFU-GEMM, CFU-GM and BFU-E
colony formation, according to the manufacturer’s instructions.
Clonogenic common lymphoid progenitors were evaluated in
MethoCult M3230 (StemCell Technologies) supplemented with
murine recombinant SCF (100 ng/ml), IL-7 (10 ng/ml and Flt-3-
L (20 ng/ml). All cultures were incubated at 37uC in a humidified
chamber under 5% CO2.




2 BMC/ml were incubated at 37uC with 5 mM CFSE
(Invitrogen) in PBS. After 10 min, a 5-fold excess of ice-cold PBS
was added to stop the reaction. Cells were then centrifuged, re-
suspended and cultured for 72 h in serum-free StemSpan medium
supplemented with IL-3, IL-6 and SCF (10, 10 and 50 ng/ml,
respectively, with or without CB (10
25 M). Thereafter, they were
labeled with APC-conjugated anti-c-kit antibody and CFSE
fluorescence was analyzed in c-kit
+ cells.
After incubation, 10
5 cells were labeled with FITC-conjugated
c-kit antibody, fixed in PBS 1% formaldehyde-free methanol that
was removed before treatment with 1 ml of PI/Triton X100
(20 mg/ml/0.1%)+DNase-free RNase (0.2 mg/ml) for 30 min at
room temperature. In some experiments magnetically sorted c-kit
+
BMC were incubated for 2 h in StemSpan medium with growth
factor cocktail alone or in the presence of CB (10
25 M), dbcAMP
(5610
24 M), forskolin (10
25 M) with or without CB. The cell
cycle status was then assessed using Vybrant DyeCycle Violet
(VDV) Stain, according to the manufacturer’s instructions. The
effect of Bordetella pertussis toxin (100 ng/ml) on the cell cycle arrest
promoted by CB was evaluated in the same conditions. After
incubation, cells were analyzed using FlowJo sofware.
In vivo experiments
The cell cycle status of bone marrow CFU-C was analyzed after
three i.p. injections of CB at a concentration of 30 mg/kg each at
24, 16 and 4 h before sacrifice. Bone marrow cells were then
recovered, incubated overnight at a concentration of 10
6 cells/ml
in growth factor cocktail (10 ng of IL-3, 10 ng of IL-6 and 50 ng of
SCF per ml) followed by PI staining and cell cycle analysis among
gated Lin
2 cells.
The myeloprotective effect of CB-induced cell cycle arrest was
assessed after treatment with AraC or cyclophosphamide (En-
doxan: Baxter, France). Mice received three i.p. injections of CB at
a dose of 20 mg/kg, at 24 and 4 h before, as well as 24 h after
chemotherapy. AraC and cyclophosphamide were given i.p. at a
dose of 350 mg/kg and 300 mg/kg, respectively. Mice were
sacrificed on day 2 post-chemotherapy, when white blood cells
were counted and colony-forming cells were evaluated in
methylcellulose in response to IL-3.
Western blotting, cell cycle microarray and H4R silencing
Whole-cell extracts for Western blot analysis were prepared
from freshly sorted c-kit
+ cells after a 5-h incubation in StemSpan
medium with growth factors alone or together with CB. 30 mg
extracts were prepared from washed cells in 100 ml extraction
buffer. They were subjected to SDS-PAGE and transferred onto
nitrocellulose sheets (Hybond C, Amersham Biosciences). Protein
transfer was ascertained by Ponceau red coloration. Membranes
were then washed with PBS and blocked with PBS-Tween 0.1%-
gelatin 0.5% for 1 h at room temperature. Blotting with
monoclonal anti-cyclin E antibodies (Santa Cruz Biotechnology)
was performed according to the manufacturer’s instructions. The
same membranes were then stripped and reprobed with
monoclonal antibodies against p21
Waf1/Cip, p-Erk1/2, Erk 1/2,
actin (Santa Cruz Biotechnology) or p27
Kip1 (Pharmingen). Oligo
GEArrayH assays were performed with freshly isolated sorted c-
kit
+ BM cells or after a 3-h incubation in the presence of growth
factor cocktail with or without CB. RNA was extracted and
amplified with the TrueLabeling-AMP
TM Linear RNA Amplifi-
cation kit according to the manufacturer’s instructions. The array
OMM-20 contains 128 oligonucleotide probes representing genes
associated with the cell cycle. H4R silencing was performed with
freshly sorted c-kit
+ cells and expanded CD34
+ cells. For
transfection, 3 ml of HiPerFect reagent (Qiagen; Courtaboeuf,
France) and 4 ml (40 pmol) of human and 8 ml (80 pmol) of
murine H4R siRNA, scrambled FITC-labeled or unconjugated
control siRNAs (all from Santa Cruz Biotechnology) were
H4R-Induced Cell Cycle Arrest
PLoS ONE | www.plosone.org 11 August 2009 | Volume 4 | Issue 8 | e6504incubated in 50 ml x-vivo medium (Cambrex; East Rutherford,
NJ) for 20 min at room temperature. The mixture was then added
to 50 ml of cell suspension at a final concentration of 10
6 cells/ml
and incubated for 20 h, when transfection efficiency was verified
with scrambled FITC-conjugated siRNA. Cells were then
centrifuged and resuspended at a concentration of 10
5 cells/ml
in StemSpan medium with growth factor cocktail for c-kit
+ and
CD34
+ cells. The extinction of H4R protein expression was
ascertained by FACS analysis after 24 h. After 3 days of culture
with or without CB, cells were counted and their viability was
assessed by trypan blue exclusion. The cell cycle status was
assessed after an overnight incubation.
Statistics
Statistical significance was established by Student’s and Mann-
Whitney’s two-tailed t test.
Supporting Information
Figure S1 Dose response curve of cell cycle arrest induced by
CB.
Found at: doi:10.1371/journal.pone.0006504.s001 (6.01 MB
DOC)
Figure S2 Apoptosis was evaluated by Annexin-V/PI staining
after a 3-day incubation of progenitor-enriched Lin- BMC in the
presence of growth factor cocktail, with or without CB (10–5 M).
A typical experiment is depicted.
Found at: doi:10.1371/journal.pone.0006504.s002 (6.01 MB
DOC)
Figure S3 Blockade of H4R by specific antagonists abrogates
CB-induced cell cycle arrest. Cell cycle was analyzed after VDV
staining in sorted progenitor-enriched c-kit+ BM cells after a 2-h
incubation in StemSpan medium supplemented growth factor
cocktail (GF), with or without CB at a concentration of 10–5 M.
The H4R antagonists were added at a concentration of 10–5 M
10 min before CB.
Found at: doi:10.1371/journal.pone.0006504.s003 (6.01 MB
DOC)
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